Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/12/18 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/07/18 | 8-K | Current report filing |
|
5 | |
| 05/22/18 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
58 | |
| 05/22/18 | 8-K | Current report filing |
|
46 | |
| 05/22/18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
46 | |
| 05/08/18 | UPLOAD | SEC-generated letter |
|
1 | |
| 05/08/18 | DEF 14A | Definitive proxy statements |
|
20 | |
| 05/04/18 | PRER14A | Preliminary revised proxy soliciting materials |
|
20 | |
| 04/26/18 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
20 | |
| 04/11/18 | 8-K | Current report filing |
|
3 |
